Please use this identifier to cite or link to this item:
Title: Multifunctional protein nanomedicine constructs to overcome CML drug resistance
Researcher: Archana P.R
Guide(s): Manzoor Koyakutty , Krishnakumar Menon
Keywords: Clinical Pre Clinical and Health,Clinical Medicine,Medicine Research and Experimental
Nanomedicine; Chronic myeloid leukemia (CML); Cancer therapy
University: Amrita Vishwa Vidyapeetham (University)
Completed Date: 08/2014
Abstract: Drug resistance is a critical issue impeding the success of cancer therapy. A typical model of drug resistance induced therapy failure is the case of chronic myeloid leukemia (CML), a hematological malignancy affecting the myeloid progenitors of blood. In CML, the primary oncogene responsible for leukemiogenesis is BCR-ABL, which is translated in to BCR-ABL fusion protein exhibiting constitutive tyrosine kinase activity. The small molecular inhibitor, imatinib had shown excellent response in chronic phase patients. However, a certain population of patients shows refractoriness to imatinib due to the point mutations in the kinase domain and/or BCR-ABL amplification. Later, newer and more effective inhibitors were developed to overcome the drug resistance. However, those drugs also had limited success. Recent line of evidences suggests that, in addition to the aberrations in primary oncogene BCR-ABL, activation of secondary kinases also play significant roles in CML drug resistance. Accordingly, in this thesis, we have focused on the alternative mechanisms of drug resistance in CML and developed novel protein nanomedicines against key mechanistic pathways of resistance, which are otherwise less explored in the clinics as therapeutic targets. Molecular characterization of refractory CML patient samples and in vitro generated model refractory cell line K562R showed that, in addition to BCR-ABL, STAT5 was also consistently up-regulated in refractory patients compared to the drug sensitive patients. Another interesting observation was that, refractory cells showed over-expression of iron transport protein transferrin receptors (TfR1), in a correlative manner with increase in drug resistance and STAT5 expression. Based on these inputs, we developed transferrin conjugated albumin nanoparticles loaded with STAT5 inhibitor sorafenib (Tf-nAlb-Soraf) for the targeted inhibition of aberrant STAT5 through TfR1 targeted drug delivery. This transferrin conjugated albumin-bound sorafenib nanomedicine (Tf nAlb-Soraf), prepared u
Pagination: XXII, 138
Appears in Departments:Amrita Centre for Nanosciences and Molecular Medicine

Files in This Item:
File Description SizeFormat 
01_title.pdfAttached File155.94 kBAdobe PDFView/Open
02_declaration.pdf27.62 kBAdobe PDFView/Open
03_certificate.pdf107.95 kBAdobe PDFView/Open
04_dedicated.pdf48.24 kBAdobe PDFView/Open
05_contents.pdf155.86 kBAdobe PDFView/Open
06_acknowledgement.pdf47.02 kBAdobe PDFView/Open
07_abstract.pdf87.1 kBAdobe PDFView/Open
08_abbreviation.pdf87.06 kBAdobe PDFView/Open
09_list of figures.pdf50.67 kBAdobe PDFView/Open
10_list of tables.pdf25.59 kBAdobe PDFView/Open
11_chapter 1.pdf1.24 MBAdobe PDFView/Open
12_chapter 2.pdf1.89 MBAdobe PDFView/Open
13_chapter 3.pdf2.54 MBAdobe PDFView/Open
14_chapter 4.pdf1.5 MBAdobe PDFView/Open
15_chapter 5.pdf130.8 kBAdobe PDFView/Open
16_appendix.pdf39.27 kBAdobe PDFView/Open
17_publications.pdf162.5 kBAdobe PDFView/Open

Items in Shodhganga are protected by copyright, with all rights reserved, unless otherwise indicated.